Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Cyanoacrylate Skin Adhesive After Mohs Surgery or Wide Local Excision

19 oktober 2026 bijgewerkt door: University of Minnesota

A Prospective Randomized Study of Surgical Site Infection After Linear Repair With or Without Cyanoacrylate Skin Adhesive Following Mohs Micrographic Surgery and Wide Local Excision

This study will compare surgical site infection after linear repair with or without cyanoacrylate skin adhesive following Mohs micrographic surgery or wide local excision.

Adult participants undergoing Mohs micrographic surgery or wide local excision for skin cancer with a surgical defect suitable for linear repair will be stratified by suture type and randomized to standardized running epidermal suture closure with or without cyanoacrylate skin adhesive.

The primary outcome is surgical site infection within 30 days after surgery. Secondary outcomes include scar quality, treatment satisfaction, wound care burden, wound healing characteristics, antibiotic use, culture results, health care utilization related to wound concerns, and adverse events.

Studie Overzicht

Gedetailleerde beschrijving

Surgical site infection is an uncommon but clinically important complication after dermatologic surgery. Linear repairs are frequently performed after Mohs micrographic surgery and wide local excision, and closure technique may affect infection risk, wound healing, scar quality, and patient experience.

This is a prospective, randomized, stratified parallel group clinical study evaluating postoperative outcomes after standardized running epidermal suture closure with or without cyanoacrylate skin adhesive. Adult patients undergoing Mohs micrographic surgery or wide local excision for skin cancer will be screened on the day of surgery. Participants will be eligible if the surgical defect is suitable for linear repair using standardized running epidermal sutures.

Participants will be stratified by suture type. In the absorbable suture stratum, participants will be randomized using a 2×2 factorial design to fast gut or Vicryl Rapide suture material and to adhesive use or no adhesive. In the non-absorbable suture stratum, participants will receive Prolene and will be randomized to closure with or without cyanoacrylate skin adhesive.

All participants will undergo Mohs micrographic surgery or wide local excision as part of standard clinical care. Research procedures include randomization of closure approach, standardized wound photography, follow-up assessments at approximately 2 weeks and 3 months, documentation of infection or suspected infection, wound healing assessment, adverse event assessment, and patient-reported outcome measures.

The primary outcome is surgical site infection within 30 days following linear repair. Secondary outcomes include antibiotic use, wound healing metrics, patient-reported treatment satisfaction and wound care burden, scar quality using the Patient and Observer Scar Assessment Scale 3.0 Linear Scar Version, culture results and treatment descriptions when infection is suspected, health care utilization related to wound concerns, and adverse events.

Studietype

Ingrijpend

Inschrijving (Geschat)

300

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Andrew Fay
  • Telefoonnummer: 612-625-8625
  • E-mail: afay@umn.edu

Studie Contact Back-up

  • Naam: Chandler Rundle, MD
  • Telefoonnummer: 612-625-8625
  • E-mail: rundle1@umn.edu

Studie Locaties

    • Minnesota
      • Minneapolis, Minnesota, Verenigde Staten, 55420
        • Oxboro Dermatology Clinic
        • Contact:
          • Andrew Fay
          • Telefoonnummer: 612-625-8625
          • E-mail: afay@umn.edu
      • Minneapolis, Minnesota, Verenigde Staten, 55455
        • University of Minnesota Dermatologic Surgery Clinic - CSC
        • Contact:
          • Andrew Fay
          • Telefoonnummer: 612-625-8625
          • E-mail: afay@umn.edu
        • Hoofdonderzoeker:
          • Chandler Rundle, MD
      • Minneapolis, Minnesota, Verenigde Staten, 55455
        • University of Minnesota Dermatologic Surgery Clinic - MG
        • Contact:
          • Andrew Fay
          • Telefoonnummer: 612-625-8625
          • E-mail: afay@umn.edu
        • Hoofdonderzoeker:
          • Chandler Rundle, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Age 18 years or older
  • Undergoing Mohs micrographic surgery or wide local excision for skin cancer
  • Surgical defect suitable for linear repair
  • Surgical defect suitable for linear repair using standardized running epidermal sutures
  • Ability to provide informed consent
  • Ability to read at a 5th grade level or above, needed for survey administration

Exclusion Criteria:

  • Requirement for flap, graft, geometric repair, or healing by second intention
  • Active infection or severe contamination at the surgical site prior to closure
  • Known allergy or hypersensitivity to cyanoacrylate adhesive, fast gut, Vicryl Rapide, or Prolene
  • Recurrent tumor at the surgical site
  • Prior radiation therapy to the surgical site
  • Current use of systemic antibiotics for an unrelated medical condition at the time of surgery
  • Concurrent participation in another interventional research study that could confound wound healing or infection outcomes
  • Inability to comply with study procedures or follow-up visits
  • Any condition that, in the judgment of the investigator, would interfere with safe participation or interpretation of study outcomes
  • Children
  • Fetuses
  • Neonates
  • Prisoners
  • Adults lacking capacity to consent or adults with diminished or fluctuating capacity to consent
  • Non-English speakers
  • Individuals unable to read
  • Employees of the researcher

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Fast Gut Sutures With Adhesive

Participants in the absorbable suture stratum will receive standardized running epidermal closure using fast gut sutures followed by cyanoacrylate skin adhesive.

Cyanoacrylate skin adhesive will be applied in a thin, continuous layer along the repaired wound after hemostasis and epidermal closure are complete. The adhesive is an FDA-approved topical wound closure product used within its labeled indication.

Andere namen:
  • 2-Octyl Cyanoacrylate

Standardized running epidermal closure will be performed using fast gut absorbable suture material after Mohs micrographic surgery or wide local excision.

Actieve vergelijker: Fast Gut Sutures Without Adhesive

Participants in the absorbable suture stratum will receive standardized running epidermal closure using fast gut sutures without cyanoacrylate skin adhesive.

Standardized running epidermal closure will be performed using fast gut absorbable suture material after Mohs micrographic surgery or wide local excision.

Experimenteel: Vicryl Rapide Sutures With Adhesive

Participants in the absorbable suture stratum will receive standardized running epidermal closure using Vicryl Rapide sutures followed by cyanoacrylate skin adhesive.

Cyanoacrylate skin adhesive will be applied in a thin, continuous layer along the repaired wound after hemostasis and epidermal closure are complete. The adhesive is an FDA-approved topical wound closure product used within its labeled indication.

Andere namen:
  • 2-Octyl Cyanoacrylate

Standardized running epidermal closure will be performed using Vicryl Rapide absorbable suture material after Mohs micrographic surgery or wide local excision.

Actieve vergelijker: Vicryl Rapide Sutures Without Adhesive

Participants in the absorbable suture stratum will receive standardized running epidermal closure using Vicryl Rapide sutures without cyanoacrylate skin adhesive.

Standardized running epidermal closure will be performed using Vicryl Rapide absorbable suture material after Mohs micrographic surgery or wide local excision.

Experimenteel: Prolene Sutures With Adhesive

Participants in the non-absorbable suture stratum will receive standardized running epidermal closure using Prolene sutures followed by cyanoacrylate skin adhesive.

Cyanoacrylate skin adhesive will be applied in a thin, continuous layer along the repaired wound after hemostasis and epidermal closure are complete. The adhesive is an FDA-approved topical wound closure product used within its labeled indication.

Andere namen:
  • 2-Octyl Cyanoacrylate

Standardized running epidermal closure will be performed using Prolene non-absorbable suture material after Mohs micrographic surgery or wide local excision.

Actieve vergelijker: Prolene Sutures Without Adhesive

Participants in the non-absorbable suture stratum will receive standardized running epidermal closure using Prolene sutures without cyanoacrylate skin adhesive.

Standardized running epidermal closure will be performed using Prolene non-absorbable suture material after Mohs micrographic surgery or wide local excision.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Surgical Site Infection Within 30 Days After Linear Repair
Tijdsspanne: Within 30 days after Mohs micrographic surgery or wide local excision

Surgical site infection will be assessed within 30 days following linear repair after Mohs micrographic surgery or wide local excision. Surgical site infection is defined as culture-confirmed infection or strong clinical suspicion of infection when a culture cannot be obtained, including purulent discharge, erythema with edema or warmth, drainage consistent with infection, or cellulitis requiring antibiotic therapy.

Within 30 days after Mohs micrographic surgery or wide local excision

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Systemic Antibiotic Use
Tijdsspanne: Baseline through 30 days after surgery

Prophylactic and postoperative systemic antibiotic use will be documented, including indication, timing, and duration. This includes antibiotics prescribed for suspected infection at follow-up or interval visits.

Baseline through 30 days after surgery
Wound Healing Complications
Tijdsspanne: 7 to 14 days and 30 days after surgery

Wound healing will be assessed by documenting dehiscence, necrosis, delayed epithelialization, and other healing-related complications.

7 to 14 days and 30 days after surgery
Treatment Satisfaction
Tijdsspanne: 2 weeks and 3 months after surgery

Treatment satisfaction will be assessed using the Oxford Skin Cancer Treatment Scale.

2 weeks and 3 months after surgery
Wound Care Burden
Tijdsspanne: 2 weeks after surgery

Wound care burden will be assessed using a brief custom wound-care questionnaire evaluating time spent on wound care, satisfaction with the wound-care regimen, and wound-care preference.

2 weeks after surgery
Scar Quality
Tijdsspanne: 3 months after surgery

Scar quality will be assessed using the Patient and Observer Scar Assessment Scale 3.0 Linear Scar Version. Participants will complete the patient scale, and a trained blinded assessor will complete the observer scale using standardized 3-month wound photographs.

3 months after surgery
Culture Results and Infection Treatment
Tijdsspanne: Within 30 days after surgery

For wounds with suspected infection, culture organisms, antibiotic selection, treatment course, and subsequent clinical course will be summarized descriptively.

Within 30 days after surgery
Health Care Utilization Related to Wound Concerns
Tijdsspanne: Baseline through 3 months after surgery

Urgent care visits, emergency department evaluations, specialty consultations, or hospitalizations related to postoperative infection or wound complications will be documented.

Baseline through 3 months after surgery
Adverse Events
Tijdsspanne: Baseline through 3 months after surgery

Adverse events will include hematoma, allergic or irritant contact dermatitis related to suture material or cyanoacrylate adhesive, and other unexpected surgical or wound-related adverse events.

Baseline through 3 months after surgery

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Chandler Rundle, MD, University of Minnesota

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

26 oktober 2026

Primaire voltooiing (Geschat)

30 december 2028

Studie voltooiing (Geschat)

30 maart 2029

Studieregistratiedata

Eerst ingediend

21 september 2026

Eerst ingediend dat voldeed aan de QC-criteria

21 september 2026

Eerst geplaatst (Werkelijk)

28 september 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

20 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

19 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren